Zacks Reiterates “Neutral” Rating for NPS Pharmaceuticals (NPSP)
NPS Pharmaceuticals (NASDAQ:NPSP)‘s stock had its “neutral” rating reiterated by Zacks in a note issued to investors on Wednesday, StockRatingsNetwork reports. They currently have a $40.00 target price on the stock. Zacks‘ price objective would suggest a potential upside of 8.02% from the company’s current price.
Zacks‘ analyst wrote, “NPS Pharma reported earnings of $0.07 per share in the fourth quarter of 2013 as opposed to a loss of $0.14 a year ago. Favorable results in the fourth quarter of 2013 were primarily due to higher revenues. Gattex has been performing well since its U.S. launch. The company expects Gattex’s sales to increase by more than 250% in 2014. A key action date for NPS Pharma is coming up in October this year when the FDA will decide on Natpara. We remain concerned about the thin pipeline at NPS Pharma beyond Natpara. We believe the company must develop additional products to sustain growth. We see limited upside potential from current levels and hence retain our on Neutral recommendation on the stock.”
NPSP has been the subject of a number of other recent research reports. Analysts at Needham & Company raised their price target on shares of NPS Pharmaceuticals from $28.00 to $46.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Jefferies Group downgraded shares of NPS Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. They now have a $38.00 price target on the stock. Finally, analysts at TheStreet upgraded shares of NPS Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, January 20th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $40.29.
NPS Pharmaceuticals (NASDAQ:NPSP) traded down 2.21% during mid-day trading on Wednesday, hitting $37.11. 2,115,791 shares of the company’s stock traded hands. NPS Pharmaceuticals has a 1-year low of $7.35 and a 1-year high of $38.74. The stock has a 50-day moving average of $35.30 and a 200-day moving average of $29.00. The company’s market cap is $3.789 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last released its earnings data on Thursday, February 27th. The company reported $0.07 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.02 by $0.05. The company had revenue of $54.45 million for the quarter, compared to the consensus estimate of $44.22 million. Analysts expect that NPS Pharmaceuticals will post $-0.20 EPS for the current fiscal year.
In other NPS Pharmaceuticals news, Director Georges Gemayel unloaded 6,188 shares of the stock on the open market in a transaction dated Thursday, February 13th. The shares were sold at an average price of $37.70, for a total transaction of $233,287.60. Following the sale, the director now directly owns 9,000 shares in the company, valued at approximately $339,300. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a clinical-stage biopharmaceutical company.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.